 |
 |
 |
 |
 |
 |
 |
 |
 |
Longitudinal study data analysis and informative drop-out. MRC training fellowship; £234,500: 2007-2010.
Evaluation of a web based cognitive assessment battery for use in a community setting. ORCATECH; $50,000: 2007-2008.
UK Biobank Participant Resource Centre. UK Biobank; £2,500,000: 2007-2010.
National Epidemiology Wales (NEW). WORD; £150,000: 2007-2008.
High through-put mobile clinic for use in large scale studies. WORD; £235,000: 2006-2009.
UK Biobank Phase 1 Pilot Study. UK Biobank; £102,000. 2005/2006. £102K.
Biobank Cymru Consortium Protocol development. UK Biobank; £66,600: 2004-2005.
Establishing an Internationally Competitive Bioinformatics/Bioanalysis Unit to Underpin Bioscience Research Across Wales. HEFCW: £1,499,000: 2003-2006.
Long term validation study of a neuropsychological test battery in patients with Alzheimer’s disease, mild cognitive impairment and healthy elderly controls: £30,000: 2007-2009.
Designed for Life: Proposal to evaluate Strategic Framework 1: Redesigning Care 2005-08. Phase 1 2006. WORD, £59,518: 2006-2007.
OPAN (Older People & Ageing research & Development Network). WORD; £240,000, 2005-2008.
NeuroDem (Dementias and Neurodegenerative Diseases Network). WORD: £238,000: 2005 – 2008.
Clinical trials in Alzheimer’s disease, vascular dementia and Parkinson’s disease dementia. Pharmaceutical companies including Pfizer, Lundbeck, Neurochem, Myriad, Roche, Wyeth: £200,000: 2005 – 2007.
Ageism in clinical trials. Research into Ageing; £12,000: 2005-2006.
Systematic review respite care for the frail elderly. DoH; £81,121: 2005-2006.
Long term follow up of patients with Alzheimer’s disease after beta amyloid vaccination. Alzheimer’s Research Trust: £40,000: 2004-2007.
Cardiovascular risk and arterial stiffness in a Welsh population. BHF; £183,171: 2003-2006.
The pattern and causes of asymptomatic cognitive decline leading to dementia. Alzheimer’s Society; £154,056: 2002-2005.
Dignity and Older Europeans (DOE). European Commission: £550,000: 2002-2005.
Cognitive function, emotional well-being and dietary factors in the Caerphilly Cohort of older men. FSA: £61,836: 2002-2003.
The determinants of hearing loss and its impact on cognitive function and quality of life. WORD; £9,885: 2000-2001.
Caerphilly Health & Social needs study: stage III. WORD; £109,287: 2001-2002.
Neighbourhood, social deprivation and mental health: the mediating role of social cohesion. WORD; £105,000: 2007-2008.
Fone DL, Palmer SR. Housing and Neighbourhoods and Health (HANAH). Estimation of synthetic neighbourhood boundaries for multilevel research. MRC PhD Studentship. £33,000: 2003-2006
A cross disciplinary framework for evaluating the influence of the built environment on the health of the public. MRC Development Grant; £474,582: 2001 – 2003.
A decision explorer for women deciding about breast cancer treatments: BresDex. CRUK; £276,333: 2007-2009.
Randomised control trial of the effects of a web-based PSA decision explorer: Prosdex. CRUK; £140,000: 2007-2009.
Communicating risk effectively in clinical genetics - understanding the processes, achieving the benefits, and avoiding harm. A systematic review. DoH; £100,205: 2006-2007.
Evaluating decision aids for familial breast cancer; exploring women's views through focus group methodology. Tenovus; £19,983: 2005-2006.
Involving the users in meeting information needs of older disabled people and their carers. European Commission: £37,000: 2003-2004.
Developing an interactive decision explorer for men considering PSA. CRUK; £86,000: 2002-2003.
Information needs of patients with chronic disabling illness and their carers (InfoPark). European Commission: £640,000: 2001-2004.
TOPAS and Maturity Matrix. NHS Primary Research Awards; £159,000: 2001-2003
The use of shared decision-making skills and risk communication tools in common therapeutic decisions: a primary care trial. Health in Partnership programme. DoH; £258,162: 2001-2003.
Patient and family determines outcomes for adults with head injuries. WORD; £114,947: 2001-2003.
